Soligenix (SNGX) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Soligenix (SNGX) - corporate logo

The Soligenix, Inc. (SNGX) market price chart reflects the valuation of a business that generates revenue from government contracts for biodefense and lymphoma therapy, with an EV/EBITDA ratio of 0.00. High barriers to entry are secured by patents and ties to the Pentagon amid stringent FDA oversight. However, persistent funding shortages and the risk of regulatory rejection for new drugs force the company to regularly conduct secondary offerings.

Soligenix - SNGX Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/10/2026)

Summary analytical data breakdowns for soligenix.com (SNGX)

- current price and projected stock value:
Stock Price Soligenix|SNGX - Analyst Median Target
- market capitalization details:
Market Value SNGX|SNGX - Business Value
- book value of equity indicators:
Book Value per Share Soligenix|SNGX - Net Asset Value|Market Capitalization to Book Value Ratio soligenix.com|SNGX - Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Soligenix, Inc.|SNGX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Soligenix|SNGX - Company Cumulative Indebtedness|Debts to Book Capitalization SNGX|SNGX - Long-Term Debt Volume|Company Short-Term Debt Soligenix|Quick Liquidity soligenix.com
- financial results and valuation multiples details:
SNGX - Company Profit|Expected Profit Soligenix, Inc.|SNGX - Business Payback Period|Future Price to Earnings Soligenix|SNGX - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SNGX|SNGX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Soligenix|SNGX - Earnings per share for the last twelve months|Quarterly EPS earnings growth soligenix.com|SNGX - Expected net earnings per share growth this year|Earnings growth forecast for next year Soligenix, Inc.
General company analysis:BioPharma Bio SNGX
Product sample of Soligenix Inc

To assess the credit quality of Soligenix, Inc. (SNGX), the analyst compares the total enterprise value with its operating profit before taxes, depreciation, and amortization to determine the asset's fundamental value. By tracking the business's EV/EBITDA multiple on GURU.Markets, the investor observes how specialized biosafety logistics costs impact capitalization, utilizing the chart's price action to identify entry points and avoid value traps.

Analysis of competing companies

EV/EBITDA Multiple SMMT (Summit Therapeutics Inc)|Total Company Value to Operating Income Before Depreciation Ratio Moderna Therapeutics (MRNA)|PCVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TARS (tarsusrx.com) - Enterprise Value to Operating Income Before Depreciation|CRMD: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio MCRB (Seres Therapeutics Inc.)|SPRO (Spero) - EV/EBITDA Multiple|Company Value to EBITDA Scynexis SCYX|EV/EBITDA Multiple ANTX|Enterprise Value to EBITDA Ratio polypid.com PYPD|LakeShore Biopharma - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ITRM (Iterum Therapeutics PLC)|BiomX Ltd - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio 60 Degrees Pharmaceuticals SXTP|Oragenics, Inc. (OGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA opgen.com (OPGN)